The US Food and Drug Administration has approved a new monoclonal antibody to treat inhaled anthrax, considered a potential biological terrorism threat because the spores of the bacterium are resistant to destruction and can be spread in the air. ---Subscribe to MedNous to access this article--- Regulation & Policy Company News